Laura Antonaci
Overview
Explore the profile of Laura Antonaci including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
28
Citations
479
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Trucco F, Lizio A, Roma E, Di Bari A, Salmin F, Albamonte E, et al.
J Clin Med
. 2024 Sep;
13(18).
PMID: 39336946
Sleep disorders have been poorly described in congenital (CDM) and childhood (ChDM) myotonic dystrophy despite being highly burdensome. The aims of this study were to explore sleep disorders in a...
2.
Pane M, Stanca G, Ticci C, Cutrona C, de Sanctis R, Pirinu M, et al.
Eur J Pediatr
. 2024 Apr;
183(7):2995-2999.
PMID: 38634892
Neonatal screening for SMA has allowed the identification of infants who may present with early clinical signs. Our aim was to establish whether the presence and the severity of early...
3.
Buchignani B, Cicala G, Cumbo F, Ricci M, Capasso A, Ticci C, et al.
Arch Dis Child
. 2024 Jan;
109(5):395-401.
PMID: 38290776
Objective: The aim of this study was to assess early language acquisitions in treated individuals with spinal muscular atrophy (SMA) type 1 and in infants identified by newborn screening (NBS)....
4.
Coratti G, Lenkowicz J, Pera M, DAmico A, Bruno C, Gulli C, et al.
J Neurol Neurosurg Psychiatry
. 2023 Sep;
95(3):235-240.
PMID: 37739783
Background: Type II spinal muscular atrophy (SMA) often leads to scoliosis in up to 90% of cases. While pharmacological treatments have shown improvements in motor function, their impact on scoliosis...
5.
Buchignani B, Cicala G, Moriconi F, Ricci M, Capasso A, Coratti G, et al.
Neuromuscul Disord
. 2023 Sep;
33(10):711-717.
PMID: 37709650
There has recently been some concern on possible cognitive impairment in patients with Spinal Muscular Atrophy (SMA). The aim of this study was to assess cognitive profiles in type II...
6.
Pera M, Coratti G, Casiraghi J, Bravetti C, Fedeli A, Strika M, et al.
J Clin Med
. 2023 Jul;
12(13).
PMID: 37445216
The primary aim of this study was to explore current caregivers' expectations on possible functional changes following treatment in comparison to data obtained in the pre-pharmacological era. A questionnaire, previously...
7.
Antonaci L, Pera M, Mercuri E
Eur J Pediatr
. 2023 Apr;
182(7):2935-2942.
PMID: 37067602
The natural history of spinal muscular atrophy has been radically changed by the advent of improved standards of care and the availability of disease-modifying therapies. The aim of this paper...
8.
Coratti G, Pera M, DAmico A, Bruno C, Bovis F, Gulli C, et al.
Neuromuscul Disord
. 2022 Dec;
32(11-12):879-885.
PMID: 36456406
The aim of this study is to retrospectively assess onset and progression of scoliosis in type II SMA patients not treated with the approved disease modifying treatments. Scoliosis was evaluated...
9.
Pane M, Coratti G, Pera M, Sansone V, Messina S, DAmico A, et al.
Ann Clin Transl Neurol
. 2022 Feb;
9(3):404-409.
PMID: 35166467
The study reports real world data in type 2 and 3 SMA patients treated for at least 2 years with nusinersen. Increase in motor function was observed after 12 months...
10.
Coratti G, Pera M, Montes J, Scoto M, Pasternak A, Bovis F, et al.
Neuromuscul Disord
. 2022 Jan;
32(1):36-42.
PMID: 34980538
The aim of the study was to establish 24-month changes in a large cohort of type II and III spinal muscular atrophy (SMA) patients assessed with the Revised Upper Limb...